Sign up for the QMED & MD+DI Daily newsletter.
Breaking the Barriers to Investment
March 1, 2004
1 Min Read
Originally Published MX March/April 2004
The natural enemy of investment in any industry is unpredictability. World events and market forces that can cause sudden and unexpected turns in the marketplace are understandably nerve-racking for those whose willingness to invest depends on the predictability of obtaining a timely return.
When seeking to reassure skittish investors, executives of regulated medical technology companies suffer from a double dose of unpredictability. Medtech companies are subject not only to general market forces, but also to the policy issues and budget constraints that all too often prevent regulatory agencies from acting in a timely fashion. Such regulatory unpredictability can severely hamper the ability of medtech companies to raise funding.
Today, most medtech investors believe that reforms implemented at FDA have reduced the unpredictability associated with that agency. Instead, they say, their greatest concern is for the processes used to determine reimbursement coverage and payment rates--especially those of the Centers for Medicare and Medicaid Services.
You May Also Like
Pedersen's POV graphic featuring the headshot of MD+DI Senior Editor Amanda Pedersen and a pull quote from the latest edition of her opinion column.
BioSig's Ridiculously Sparse Layoff Announcement Reeks of CallousnessFeb 26, 2024|3 Min Read
Sourcing Electrical Components: Are We Back to Normal?Feb 26, 2024|6 Min Read
Your Smartwatch Can’t Measure Blood Glucose Levels… YetFeb 26, 2024|3 Min Read
Medtech in a Minute: Medtronic Pulls the Plug on Ventilators and MoreFeb 26, 2024|1 Min Read